PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. - Wikidata - wikimedia - TriplyDB

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

http://www.wikidata.org/entity/Q36458927

about

Regulation of inflammation in cancer by eicosanoids The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?EET signaling in cancer Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway.Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.Effects of PPARα inhibition in head and neck paraganglioma cells The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.PPARalpha: energy combustion, hypolipidemia, inflammation and cancer Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells.Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53 Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis.Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.Anti-tumoral effects of miR-3189-3p in glioblastoma Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia.Nuclear receptors as modulators of the tumor microenvironment.Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells.Radiation-induced cognitive impairment--from bench to bedside NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.PPARα modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis Macrophages, PPARs, and Cancer.PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.Role of peroxisome proliferator-activated receptor alpha and gamma in antiangiogenic effect of pomegranate peel extract.Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential Drug Repurposing for Oral Cancer.

P2860

Q24564308-A47F52F8-3491-4B13-ABBA-CBFDB4609629 Q24601222-AA93B66A-0B80-47F4-B50F-57F68A54FAFD Q26824893-7A55F27E-4353-42FF-AB96-844CA6996C5F Q28250730-16E72271-63D0-4E43-BD59-34F1AF892BE3 Q28743072-F87344EE-966B-42B5-B36B-0EF450C8FDB0 Q33589182-3C1F4832-E010-460D-A867-84EC40EC5AAE Q33642616-3A36860A-80EA-408E-88E9-620652B600D0 Q33688755-C7AA5E1E-9F45-4DBE-8ACE-B51F42ACA1E4 Q33692555-5B9B59F8-A885-4C52-A73D-73584FCE1E6E Q33755975-0C777565-79EF-43DA-BBF0-14F5F3CCBC8D Q33779008-02B198C8-2105-4753-B646-2EBB55DB6EA4 Q33800226-D23B8BB8-C8B5-4D8E-A6D3-9D950D4789B4 Q33805104-80C11194-50CF-4005-BE82-7CA769503A3B Q34149881-AB0228D5-D9FF-424F-A4BA-9A16970D15A1 Q34358307-3AF20FE3-5721-45DF-9E9F-D745DA0B90C6 Q34402079-D36DAD0A-1BB8-4B77-87AB-8AD2977CB9BC Q34483561-961814A4-A6E7-45DB-8AF0-11F6809C0913 Q34487653-A76547BF-0804-41BE-ABFE-D3CB8750E9E8 Q34620720-071C5747-D14F-41C4-81F2-B327FFD2CE53 Q34851156-E5605B6F-5DD8-4DE3-816A-903469A37349 Q34948760-51DC119A-FC52-41E4-9657-2522A45F66A2 Q34968487-A64A6688-8AA2-4002-87D9-C40558C5F43B Q35050146-18106989-E2BC-4331-9701-BB7119D229EC Q35092818-0932C2DC-2FD8-4C77-B41B-AE1A6977CEA4 Q35098905-97F99CCF-8413-477E-8F6D-367EFFE99806 Q35116804-9F40C979-16F9-49A4-BC33-7AA2108208BF Q35221508-A9BF8F39-CE85-4481-9439-AD63DE3C719E Q35640579-41F5466F-69CC-462C-BDBE-5F5FB464BBB1 Q36081467-55CFD347-C338-4955-BD8E-D8E032C9D0BF Q36127288-26714177-E984-4330-B240-574958F9601D Q36318813-EA906FF3-C6B8-4ECA-9863-FA1C1AA17A38 Q36344693-80A08239-2EF5-4AAC-8433-450155CC9409 Q36413381-08124104-604B-4D2D-91A1-24CFAE4A7BD0 Q36477296-72876ED6-BCD1-4175-888F-AFC94322B777 Q36573120-9335C519-A539-492A-85DD-87443971034E Q36743885-AD921F2A-6F06-4D4A-BD93-B805BD99B5E7 Q36772391-4653B991-FB79-4C81-932F-F01B1589D046 Q36773772-0F5F12D2-24E8-49D1-A0E0-D5BB2CFE3672 Q36781253-92167159-D1B2-4430-ACCD-2CAE34952AA1 Q37012110-31F32CB2-9790-4E1E-B5A5-DEA7CE9979B6

P2860

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

http://www.wikidata.org/entity/Q36458927

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@ast

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@en

type

label

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@ast

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@en

prefLabel

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@ast

PPARalpha agonist fenofibrate ...... irect angiogenesis inhibition.

@en

P1433

Q36458927-DFB92781-4449-4FE2-BEAC-3412AA0DBF32

P1476

Q36458927-5AF3F025-481C-4FE3-9EB0-A254BECAD973

P2093

Q36458927-01962D8D-D43F-4785-9A3A-43CAA73FE9AC

Q36458927-288BAB29-35E9-47C6-A7A5-903C1C9024FB

Q36458927-31B68595-742F-41D6-ADC8-7F7F71ED3670

Q36458927-8FAADED8-2932-4869-B2EE-A12033779976

Q36458927-B2A0D083-DAD5-4144-ABB9-B555378D3F2B

Q36458927-BAC11493-21F8-4FE6-8FEB-A03B28D46503

Q36458927-C12B755B-3FAB-4C61-9272-413E195ECD0E

Q36458927-D23728F9-DA33-4C03-AED8-FE1E9D8D2968

Q36458927-E336219B-3396-45E7-91FE-9346B762B566

P2860

Q36458927-15F7C7B4-64DF-4FA2-AB8A-0674E924D1FE

Q36458927-185C85BF-30FB-4D6B-90A6-50470F6FDFE8

Q36458927-1889BEFA-DE79-4B37-B03D-0277FDFD60FB

Q36458927-1AB3D3A9-FE24-4514-9F7E-9C9942C32CE3

Q36458927-28902FD5-201C-4522-AEDE-4F3FC8AFD7DF

Q36458927-2B51B767-1102-4CFF-B1F7-A0918616F7FC

Q36458927-2BDB184E-88A0-43A5-941B-3F45AF140966

Q36458927-2D318AA3-54D9-4614-9C44-10DCA4E2B338

Q36458927-31A95290-3E45-40C5-A42F-D1F2E059490F

Q36458927-3D8D553C-2676-4880-9AF3-CAF21E3DDCFF

P304

Q36458927-F77595EA-3180-4F40-8B16-49C2B8F47463

P31

Q36458927-BFB5C73C-9E3B-4D36-A481-5FB413E0D798

P356

Q36458927-27DA27B6-8D02-4D2D-950D-69A3023F84F7

P407

Q36458927-F1FE4236-C81A-4D00-A050-DCB41C815C0F

P433

Q36458927-59B7AF28-871F-436E-AEFD-F8B2D9AD9581

P478

Q36458927-E7AD1EB3-3E02-4291-B260-52CF547A83D9

P50

Q36458927-E256C5A3-A5BC-46C5-AA44-98CB4456409C

P577

Q36458927-397DFC93-AA5B-4D51-9F46-1ECC91B668FD

P5875

Q36458927-DD916920-B0B6-4724-B467-305393B9C284

P698

Q36458927-0B854060-0FE2-4CA1-90A2-910893E45C41

P932

Q36458927-3213E792-3433-4B5E-934E-BD5E4861931B

P356

PNAS.0711281105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

PPARalpha agonist fenofibrate ...... direct angiogenesis inhibition

@en

P2093

Andrea M Laforme

http://www.w3.org/2001/XMLSchema#string

Arja Kaipainen

http://www.w3.org/2001/XMLSchema#string

Carmen M Barnés

http://www.w3.org/2001/XMLSchema#string

Catherine E Butterfield

http://www.w3.org/2001/XMLSchema#string

Deviney M Chaponis

http://www.w3.org/2001/XMLSchema#string

Dipak Panigrahy

http://www.w3.org/2001/XMLSchema#string

Judah Folkman

http://www.w3.org/2001/XMLSchema#string

Michael Fannon

http://www.w3.org/2001/XMLSchema#string

Sui Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Inflammation and cancer

Tumor angiogenesis: therapeutic implications

The mechanisms of action of PPARs

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

The PPARs: from orphan receptors to drug discovery

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

Endostatin's antiangiogenic signaling network.

Peroxisome proliferator-activated receptors and inflammation.

P304

985-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0711281105

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5651368

http://www.w3.org/2001/XMLSchema#string

P698

18199835

http://www.w3.org/2001/XMLSchema#string

P932

2242705

http://www.w3.org/2001/XMLSchema#string